- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00174915
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. (APEX)
January 31, 2012 updated by: Takeda
A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.
The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A Phase 3 Study comparing 80 mg, 120 mg or 240 mg of febuxostat, allopurinol (300 mg for those with normal renal function and 100 mg for those with impaired renal function) and placebo administered once daily in subjects with gout.
Subjects will receive treatment for 28 weeks.
Study Type
Interventional
Enrollment (Actual)
1072
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hyperuricemia (serum urate ≥8.0 mg/dL and gout by American Rheumatism Association Criteria
- Renal function defined as a serum creatinine level of < 2.0 mg/dL and creatinine clearance of > 20 milliliters per minute (mL/min) by Cockroft and Gault formula.
Exclusion Criteria:
- History of xanthinuria
- Intolerance to allopurinol
- Presence of renal calculi,
- Alcohol intake of ≥ 14 drinks/week
- Clinically significant medical condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo QD
|
Placebo, orally, once daily for up to 28 weeks.
|
Experimental: Febuxostat 80 mg QD
|
Febuxostat 80 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 120 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 240 mg, orally, once daily for up to 28 weeks.
Other Names:
|
Experimental: Febuxostat 120 mg QD
|
Febuxostat 80 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 120 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 240 mg, orally, once daily for up to 28 weeks.
Other Names:
|
Experimental: Febuxostat 240 mg QD
|
Febuxostat 80 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 120 mg, orally, once daily for up to 28 weeks.
Other Names:
Febuxostat 240 mg, orally, once daily for up to 28 weeks.
Other Names:
|
Active Comparator: Allopurinol QD
|
Allopurinol, orally, once daily for up to 28 weeks.
Dose of allopurinol received was based on renal status.
Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).
Time Frame: Last 3 visits (any last 3 visits up to week 28)
|
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable.
A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used.
The last 3 visits used may have differed for each subject.
|
Last 3 visits (any last 3 visits up to week 28)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28
Time Frame: Week 28
|
Serum urate values were obtained at the Week 28 visit.
The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized.
|
Week 28
|
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit
Time Frame: Final Visit (up to 28 weeks).
|
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized.
The final visit was the last visit at which a serum urate value was collected and may have differed by subject.
|
Final Visit (up to 28 weeks).
|
Percent Change From Baseline in Serum Urate Levels at Week 28.
Time Frame: Baseline and Week 28
|
Serum urate values were obtained at the Week 28 visit.
The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized.
|
Baseline and Week 28
|
Percent Change From Baseline in Serum Urate Levels at Final Visit
Time Frame: Baseline and Final Visit (up to 28 weeks)
|
The percent change in serum urate from baseline to the Final visit was summarized.
The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100.
The final visit was the last visit at which a serum urate value was collected.
The timing of the final visit may have differed for each subject.
|
Baseline and Final Visit (up to 28 weeks)
|
Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
Time Frame: Baseline and Week 28
|
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit.
If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.
|
Baseline and Week 28
|
Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
Time Frame: Baseline and Final Visit (up to 28 weeks)
|
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening.
If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.
|
Baseline and Final Visit (up to 28 weeks)
|
Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.
Time Frame: Baseline and Week 28
|
Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit.
If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0.
|
Baseline and Week 28
|
Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit
Time Frame: Final Visit (up to 28 weeks)
|
Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening.
If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.
|
Final Visit (up to 28 weeks)
|
Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.
Time Frame: Weeks 8 through 28
|
Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized.
A subject who reported more than 1 gout flare during this period was counted only once.
|
Weeks 8 through 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
- Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032.
- Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.
- Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
April 1, 2004
Study Completion (Actual)
April 1, 2004
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Estimate)
February 2, 2012
Last Update Submitted That Met QC Criteria
January 31, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Gout
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Allopurinol
- Febuxostat
Other Study ID Numbers
- C02-009
- U1111-1113-9740 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Febuxostat
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouUnknown
-
University of Mississippi Medical CenterTerminatedBlood Pressure | GoutUnited States
-
Benha UniversityNew Jeddah Clinic HospitalCompletedHemodialysis Complication | Hyperuricemia
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Ningbo No. 1 HospitalNot yet recruitingNonalcoholic Fatty Liver DiseaseChina
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
AstraZenecaCompletedType 2 Diabetes | Albuminuria | HyperuricemiaUnited States
-
TakedaCompleted